Physician profile
John L Harding
NPI 1457318776
$5,542.96
in general payments reported to CMS, 2019-2025
34 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $189 · 2021: $886 · 2022: $978 · 2023: $713 · 2024: $892 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994 · Travel and Lodging: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.59 |
| Travel and Lodging | $1,154.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,451.27 | 2021-2025 | |
| Abbvie INC. | $544.84 | 2019-2023 | |
| Exeltis, USA INC. | $456.21 | 2022-2025 | Slynd, Solosec |
| Amgen INC. | $441.80 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $404.10 | 2019-2025 | |
| Minerva Surgical, INC | $361.95 | 2021-2023 | |
| Travere Therapeutics, INC. | $359.96 | 2023-2025 | |
| Organon LLC | $275.59 | 2022-2025 | Nexplanon |
| Novo Nordisk INC | $224.66 | 2022-2025 | Wegovy, Ozempic |
| Mayne Pharma Commercial LLC | $84.00 | 2022-2023 | |
| Vifor Pharma, INC. | $78.44 | 2023 | Korsuva, Veltassa |
| Biogen, INC. | $70.15 | 2025 | Zurzuvae |
| Convatec INC. | $65.67 | 2019-2021 | |
| Hologic Sales and Service, LLC | $65.49 | 2019-2021 | |
| Astellas Pharma US INC | $60.64 | 2022-2025 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $56.17 | 2022 | |
| Therapeuticsmd, INC. | $49.88 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $47.23 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $47.13 | 2019-2020 | |
| Avion Pharmaceuticals | $47.06 | 2019-2021 | |
| Pfizer INC. | $39.80 | 2023-2024 | |
| Coopersurgical, INC. | $35.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.44 | 2023 | Ultomiris |
| Amag Pharmaceuticals, INC. | $31.40 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $30.28 | 2021 | |
| Abbott Laboratories | $30.21 | 2023 | Proclaim |
| Evofem Biosciences, INC. | $27.39 | 2021 | |
| Aspira Women'S Health INC | $24.86 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.87 | 2023 | Acthar |
| Daiichi Sankyo INC. | $17.73 | 2024 | Injectafer |
| Allergan, INC. | $17.48 | 2019 | |
| Medtronic, INC. | $17.19 | 2024 | Ligasure |
| Sumitomo Pharma America, INC. | $13.78 | 2024 | Gemtesa |
| Lsi Solutions INC | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.